Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $18.6 million.

  • Fulcrum Therapeutics' Cash from Investing Activities rose 32786.21% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 2958.36%. This contributed to the annual value of $32.2 million for FY2024, which is 18783.93% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Cash from Investing Activities stood at $18.6 million for Q3 2025, which was up 32786.21% from $13.9 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Cash from Investing Activities high stood at $38.1 million for Q1 2024, and its period low was -$106.6 million during Q3 2021.
  • For the 5-year period, Fulcrum Therapeutics' Cash from Investing Activities averaged around -$4.7 million, with its median value being $4.4 million (2024).
  • In the last 5 years, Fulcrum Therapeutics' Cash from Investing Activities plummeted by 1156106.19% in 2021 and then surged by 93457.66% in 2023.
  • Fulcrum Therapeutics' Cash from Investing Activities (Quarter) stood at -$9.1 million in 2021, then plummeted by 299.85% to -$36.4 million in 2022, then surged by 150.48% to $18.4 million in 2023, then tumbled by 87.69% to $2.3 million in 2024, then surged by 723.54% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q3 2025, $13.9 million for Q2 2025, and -$777000.0 during Q1 2025.